Gene Transcription and Therapeutic Intervention
June 2-3, 1997
The Loews L’Enfant Plaza, Washington D.C.
Regulation of gene transcription lies in the heart of signal
transduction process. Changes in cell behavior during health and
disease induced by growth factors or cytokines, require execution of
selective gene transcription. Significant progress has been made in
our understanding of how extracellular or intracellular signals can
regulate sets of genes in a selective fashion. Cloning and
identification of novel transcription factors (from genomics projects)
gives us the opportunity for developing pioneering therapeutic
approaches. Development of agents that regulate gene expression
represent a new and unexploited area for small molecule therapeutics.
Selective regulation of transcription with small molecules will emerge
as a dominant gene therapy mode in 21st century.
This conference brings together leaders in the field of transcription
regulation, both from academia and industry. First session deals with
basic aspect of signal transduction, gene regulation and its
importance in drug development. Enormous progress has been made in
nuclear receptor function and how they are used as models for
transcription factors-drug interaction. Sessions are also planned
that discuss roles of specific transcription factors in diseases, for
example, cancer, cardiovascular disease and inflammation. Pathogen
transcription apparatus is discussed as a therapeutic target from
fungal and bacterial and viral perspective. A full session is devoted
to exciting development from genomics and its impact in generation of
transcription factors as drug targets.
Signal Transduction and Transcription Regulation
Regulation of Transcription: An Emerging New Area for Therapeutic
Intervention
Dr. Tauseef R. Butt, Gene Transcription Technologies; University of
Pennsylvania School of Medicine (confirmed)
In Vivo and In Vitro Analyses of the hsp70 Heat Shock Gene Promoter in
Drosophila
Dr. David S. Gilmour, The Pennsylvania State University (confirmed)
Lac Repressor: A Model Transcription Factor with Fascinating
Regulatory Modes of Action
Dr. Mitch Lewis, University of Pennsylvania Medical School
Activation of Latent Transcription Factors in Response to Signal
Transduction
Dr. Joseph Didonato, University of California School of Medicine
Nuclear Receptors as Model Transcription Factors
Human Estrogen Receptor: A Rich History of a Receptor With Multiple
Physiological Effects
Dr. Leslie Pike, University of Cincinnati
Nuclear Receptor Coregulatory Proteins: A New Frontier of Hormone
Action and Transcriptional Regulation
Dr. Paul G. Walfish, University of Toronto Medical School and Mount
Sinai Hospital(confirmed)
Androgen Receptor and Co-activator Interaction
Dr. Chawshang Chang University of Wisconsin
Expression of PPARs and Their Role in Physiology
Dr. Walter Wahli, University of Lausanne
Emerging Concepts and Bioinformatics Approaches in Transcription
Regulation Advanced Data Management Tools for the Study of Gene
Expression
Dr. G. Christian Overton, University of Pennsylvania (confirmed)
Patterns of Gene Expression: A Bioinformatics Approach to Identifying
Master Transcription Regulators
Dr. Frank Tobin, SmithKline Beecham Pharmaceuticals (tentative)
Gene Expression Micro-Arrays: A New Tool for Genomics
Dr. Deval A. Lashkari, Synteni, Inc. (confirmed)
Sequencing and Analysis of Human Regulatory Regions
Dr. Marc Vasseur, Genset (confirmed)
Transcription Regulation: The Other End of Gene Therapy Challenge
Dr. Inder Verma, The Salk Institute
Transcription Factors, Apparatus and Therapeutic Intervention
Rapid Screening of DNA Binding Molecules in Developing Small Molecule
Gene-regulating Drugs
Dr. Cynthia Edwards, Genelabs Technologies, Inc.
Microbial Transcription Apparatus as a Novel Antimicrobial Drug Target
Dr. C. Richard Wobbe, Scriptgen Pharmaceutical (confirmed)
Activation of RXR Pathway Modulates Apoptosis in Myeloid and Lymphoid
Cells
Dr. Richard A. Heyman, Ligand Pharmaceuticals
E2F Transcription Factor as Anticancer Targets
Dr. Roberto Wienman, Bristol-Myers Squibb Pharmaceutical Research
Institute (confirmed)
Topic to be Determined
Dr. David Kirn, Onyx Pharmaceuticals
Oncogene Sciences, Inc.
Regulation of HDL Gene Expression and Cardiovascular Function
Dr. Sotirios K. Karathanasis, Wyeth-Ayerst Research (confirmed)
Peroxisome Proliferator Receptor Modulating Drugs and Their Role in
the Treatment of Non-Insulin Dependent Diabetes
Dr. Paul Young, SmithKline Beecham Pharmaceuticals (confirmed)
Therapeutic Intervention of Cytokine Signaling: Molecular Targets and
Screening Strategies
Dr. Casey C. Case, Tularik, Inc. (confirmed)
Complex Regulation of NF-Kappa B During the Inflammatory Response
Dr. Steven M. Taffet, State University of New York Health Science
Center at Syracuse (confirmed)
NF-AT Family of Transcription Factors and Cytokine Gene Regulation
Dr. Anjana Rao, Harvard Medical School
For registration and hotel information, please contact:
Cambridge Healthtech Institute
1037 Chestnut Street
Newton Upper Falls, MA 02164
USA
Phone: 617-630-1300
Fax: 617-630-1325
e-mail: chi at healthtech.comhttp://www.healthtech.com/conferences/
______________________________
Cambridge Healthtech Institute
1037 Chestnut Street
Newton Upper Falls, MA 02164
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
tel: 617.630.1300
fax: 617.630.1325
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
inquiries at healthtech.com
World Wide Web http://www.healthtech.com/conferences
